Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Swiss biopharmaceutical firm Neurimmune has partnered with German biotechnology company Ethris to develop mRNA-based, neutralising antibodies for a Covid-19 therapeutic formulated for inhalation.
As part of the alliance, Neurimmune will combine its human antibodies development expertise with Ethris’ SNIM RNA therapeutics platform.
Neurimmune will use high-throughput immunoglobulin sequence analyses from patients recovered from the novel coronavirus infection.
The partners will co-develop immunotherapy to generate therapeutic antibodies directly in patients’ lungs, expected to be effective in all types of patients.